c-Abl inhibitors
Nilotinib-style and PD-purposed c-Abl tyrosine-kinase inhibitors (vodobatinib, IkT-148009 / risvodetinib).
State of the art
No update yet for c-Abl inhibitors. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
No reader summaries on this topic yet.